Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. The company has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome (PWS) and other rare and serious forms of obesity. Zafgen is well-capitalized and has assembled a team accomplished in bringing therapies to patients affected by metabolic disease.

Headquarters Boston, MA
Pipeline Phase 2, pre-IND and preclinical programs
Twitter @Zafgen